KLRS
NASDAQ · Biotechnology
Kalaris Therapeutics Inc
$8.34
-0.01 (-0.12%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 21.76M | 20.47M | 20.59M |
| Net Income | 3.46M | 2.44M | 2.89M |
| EPS | — | — | — |
| Profit Margin | 15.9% | 11.9% | 14.1% |
| Rev Growth | +16.8% | +12.7% | +4.6% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 57.89M | 48.02M | 48.60M |
| Total Equity | 75.24M | 68.16M | 76.24M |
| D/E Ratio | 0.77 | 0.70 | 0.64 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 6.13M | 5.18M | 5.24M |
| Free Cash Flow | 2.45M | 2.75M | 2.72M |